@-month overall survival was @ % ( @ % CI @-@ ) in the lomustine group , @ % ( @-@ ) in the bevacizumab group , @ % ( @-@ ) in the bevacizumab and lomustine @ mg/m ( @ ) group , @ % ( @-@ ) in the bevacizumab and lomustine @ mg/m ( @ ) group , and @ % ( @-@ ) for the combined bevacizumab and lomustine groups .